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Abstract 
A role for the carotid body (CB) in glucoregulation has been proposed but the evidence is 
conflicting. Hypoglycaemia in vivo induces a CB-dependent hyperventilation, but it is not 
agreed whether this reflects a direct action of reduced blood glucose on the CB, or an 
indirect effect of adrenaline. We therefore investigated the effects of adrenaline and 
hypoglycaemia upon ventilation. 
Ventilation (VE) was recorded during infusions of adrenaline or insulin (to induce 
hypoglycaemia) in anaesthetized male Wistar rats. CB-mediated effects were determined 
by application of hyperoxia at each dose. This was repeated during propranolol infusion. 
Hypercapnia was applied at control and at the end of adrenaline or insulin infusion.  
Adrenaline and hypoglycaemia evoked increases in VE, without an associated change in 
PaCO2. Hyperoxia reduced baseline VE and offset the ventilatory responses. Propranolol 
reduced baseline VE and abolished the hypoglycaemia-mediated ventilatory increase, but 
an increased PaCO2 occurred. Both hypoglycaemia and adrenaline increased the 
hypercapnic ventilatory response, which was blocked by propranolol. 
These data suggest that adrenaline may underlie the increased VE seen in hypoglycaemia 
via a β-mediated, O2 independent pathway within the CB. It also suggests that the 
increased VE during hypoglycaemia is a hyperpnoea that is appropriate to the increased 
metabolism. 
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1.  Introduction 
1.1 Ventilation and its control  
Ventilation is the volume of air entering the lungs per minute (VE, ml.min-1), and is equal to 
the product of respiratory frequency (Rf  – number of breaths per minute) and tidal volume (Vt 
– mls of air entering lungs with each inspiration). VE is controlled by three parts of the 
respiratory system; the controller residing in the CNS, the effector respiratory muscles and the 
afferent sensory input from chemoreceptors and other receptors. The central controller system 
is located in 2 regions: the pons and medulla of the brainstem, and the cortex. The brainstem is 
responsible for automatic breathing via three groups of respiratory neurones, which generate 
the respiratory rhythm. The cortex allows voluntary control over breathing and can override 
the central pattern generator of the brainstem up to a point. The respiratory muscles are 
controlled by these central regions to co-ordinate in the action of breathing. The respiratory 
sensors detect changes in the chemical environment of the blood/ECF. They provide 
information to the central controller to make necessary changes in ventilation and receive 
feedback from the effector muscles. The sensors can be divided into three groups: central 
chemoreceptors, peripheral chemoreceptors and other (largely mechanical) receptors (West, 
2012). The central chemoreceptors are located in the medulla near to the respiratory neurones, 
and respond to changes in the [H+] of the ECF surrounding them. A decrease in pH leads to 
increased VE. The ECF composition is mainly determined by the CSF, which is separated 
from the blood by the blood brain barrier. Therefore central chemoreceptors cannot respond 
directly to blood [H+]. However CO2 can diffuse from the cerebral vessels across the barrier, 
leading to an increase in [H+] (according to the Henderson-Hasselbach equation). This 
stimulates the chemoreceptors to induce hyperventilation, decreasing CO2 and therefore [H+], 
and correcting pH. In this way, PaCO2 (partial pressure of CO2 in the arterial blood) is the 
major controller of VE via its effect on the pH of the CSF, and the central chemoreceptors are 
the most important respiratory sensors in the breath-by-breath control of VE (West, 2012). 
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Peripheral chemoreceptors: The carotid body 
The peripheral chemoreceptors are present in two locations; the carotid bodies (CBs) and the 
aortic bodies. The aortic bodies are present above and below the aortic arch, but their 
contribution is not as significant as that of the carotid bodies in humans. The CBs are located  
bilaterally at the bifurcation of the common carotid artery to the internal and external carotid 
arteries (Kumar and Prabhakar, 2012) (Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: A - A diagram showing the anatomical location of the carotid body (CB). They are positioned 
bilaterally at the bifurcation of the common carotid (CC) into the internal (IC) and external carotid (EC) arteries. 
They are afferently innervated by the glossopharyngeal (IXth cranial) nerve, along which chemodischarge is 
transmitted to the medulla (NTS), which contains cardiorespiratory controller neurone groups. This allows 
integration of the chemosensory information from the CB, into the characteristic cardiorespiratory reflex 
response via autonomic and respiratory motorneurones. Image taken from (Kumar, 2007). B - A diagram 
showing a closer view of the location of the CB. Here it can be seen that the afferent innervation is actually 
provided by the carotid sinus nerve, a small branch of the glossopharyngeal. Image accessed at 
http://journals.cambridge.org.  
 
 
They receive afferent innervation from the carotid sinus nerve (CSN), a branch of the 
glossopharyngeal (IXth cranial) nerve, which projects from the medulla, allowing conversion 
 a)  B A 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of chemosensory discharge information to a graded characteristic autonomic and 
cardiorespiratory reflex (Kumar, 2007).  
They are highly vascularised organs with a rich supply of capillaries, and receive up to 15 
times the blood flow of the brain, relative to size. The efferent innervations of the CB (by 
sympathetic fibres of the superior cervical ganglion) are thought to impact upon the 
chemoafferent output by modulating blood flow and hence the level of stimulus detected. The 
high blood flow results in a small arterial-venous PO2 (partial pressure of O2) difference in 
spite of a fairly high metabolic demand, facilitating their response to blood gas status (Kumar, 
2007).  
 The CBs are formed of thousands of type I (glomus) cells arranged in 3-5 cell clusters 
(glomeruli). A single type II cell, which are fewer in number than type I, associates with each 
cluster. The whole organ is surrounded by protective connective tissue. It is generally accepted 
that the type I cells are the chemosensory unit, as they make synaptic connections with 
afferent CSN fibres, and also possess gap junctions with other type I cells, whilst the type II 
cells have a supportive role much like glia (Kumar and Prabhakar, 2012).  
Stimuli of the CB are decreased PaO2 (hypoxaemia), decreased pH (acidosis) and increased 
PaCO2 (hypercapnia). Hypoxaemia is the primary stimulus, although it must be recognised that 
the type I cells will sense tissue PO2, rather than PaO2 directly. This is therefore dependent 
upon the inspired level of O2, haemoglobin concentration (O2 carrying capacity), the structure 
of the vasculature and therefore the blood flow reaching the cells, as well as the local 
metabolic demands and diffusion (West, 2012). As already discussed, the high blood flow of 
the CB is entirely adequate to meet its O2 consumption, and reasonable microvascular PO2s 
have been reported (Rumsey, 1991) (Whalen, 1973), therefore a low tissue PO2 cannot explain 
its sensitivity. This suggests that a cellular mechanism for sensing O2 must exist, which has 
been shown to lead to type I cell membrane depolarisation and a subsequent Ca2+-dependent 
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neurosecretion. The upstream sensing mechanism for this pathway is debated (see review 
(Kumar and Prabhakar, 2012)). The CB response is completely responsible for the increase in 
VE seen in response to hypoxaemia in humans, therefore CB resection (CBR) can lead to a 
loss of the hypoxic VE response. The CB will also respond to ischaemic/stagnant hypoxia and 
histotoxic hypoxia as caused by metabolic poisons (Kumar, 2007). 
The response of the CB to PaCO2 accounts for only a small proportion of the total VE response 
to hypercapnia; the majority is mediated via the central chemoreceptors. However the 
peripheral response is much faster and therefore may be useful in situations of sudden 
increases in PaCO2, increasing VE to restore isocapnia. The CB also responds to a decrease in 
arterial pH, which can be caused by metabolic or respiratory factors. The reflex increased VE 
increases excretion of CO2, helping to correct pH. The amount of CO2 in the blood has 
significant implications for the pH of the blood, as described by the Henderson-Hasselbach 
equation. VE therefore allows a large amount of control over acid-base status, although some 
control also comes from excretion of bicarbonate by the kidneys. The ratio between 
bicarbonate and PCO2 must be maintained to hold pH at 7.4, and this relationship is 
represented by the Davenport diagram. The ratio and therefore pH can be disturbed in 4 ways; 
an acidosis or alkalosis, caused by either respiratory or metabolic factors. Of relevance to 
hypercapnia is respiratory acidosis, whereby an increased PCO2 leads to a decreased 
bicarbonate/PCO2 ratio and therefore a decreased pH (West, 2012). For this reason it has been 
questioned whether CO2 directly acts on the CB, or if the response is mediated by a change in 
pH, although CO2 has been shown experimentally to have an independent effect when pH is 
maintained (Biscoe et al, 1970). As the central and peripheral chemoreceptors both respond to 
CO2/H+, but are separated by the blood brain barrier, they may actually be sensing different 
environments and appear to be out of phase with one another; however this interaction ensures 
a smooth response to hypercapnia (Schwartzstein and Parker, 2006).  
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Other respiratory receptors also exist, for example pulmonary stretch receptors. These other 
receptors tend to be stimulated by mechanical and noxious stimuli (West, 2012).  
As a decreased PO2 is the main stimulus for increased CB activity, it follows that above 
normoxic levels of PO2 i.e. hyperoxia, would ablate activity of the CB, although tonic firing 
has still been reported in vivo at PaO2s of 400-600mmHg (Kumar, 2007, Biscoe et al, 1970). 
However, despite this, hyperoxia is often used as an experimental tool, allowing a ‘chemical 
denervation’ e.g. in humans where one cannot perform a carotid sinus nerve section (CSNX), 
or in animals where use of CSNX or CBR can be technically difficult and hyperoxia provides 
the advantage of reversibility.  
 
1.2  Carotid body responses: hypoxia and hypercapnia 
The PO2 in inspired air (at sea level barometric pressure) is 150mmHg, which drops to around 
100mmHg at the alveoli (PAO2) as determined by the balance between the metabolic demand 
of the tissues and the level of VE. In a healthy lung, arterial O2 (PaO2) is only slightly different 
to PAO2, and so this level of O2 is present in the systemic circulation reaching the tissues. This 
difference is contributed to by shunted blood e.g. bronchial and coronary circulation, which 
becomes O2 depleted before entering the systemic circulation (West, 2012).  
As O2 diffuses to the mitochondria in the tissues, PO2 is lowered further to 25-30mmHg and 
below. PCO2 in the air is negligible, but PACO2 (and hence PaCO2) is around 40mmHg. 
Clearly any change in VE will affect the alveolar and hence arterial levels of O2 and CO2, for 
example hypoventilation causes PO2 to fall and PCO2 to rise (explained by the alveolar VE 
equation, as metabolic CO2 production will continue). The PO2 of blood can also be affected 
by the relationship between VE and perfusion, where a mismatch i.e. perfusion of a poorly 
ventilated region, can lead to a decreased PO2 and an increased PCO2. Hypoventilation, 
diffusion limitations, shunt and VE-perfusion mismatch are all physiological causes of 
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hypoxaemia and can also cause hypercapnia (increased PaCO2) although this tends to be 
quickly corrected by an increase in VE driven by chemoreceptors (West, 2012). 
 
Hypoxia 
As discussed, hypoxia (low O2 content) or hypoxaemia (low O2 specifically in the blood) is 
the primary and most powerful stimulus of the CB, and so has received much research 
attention. As tissue PO2 decreases and tissue becomes hypoxic, the CB type I cells respond by 
increasing Ca2+-dependent neurosecretion leading to a rapid and sustained increase in neural 
discharge, the frequency of which increases exponentially with the stimulus (reviewed by 
Kumar and Prabhakar, 2012). An example raw trace showing the increased discharge in the 
carotid sinus nerve in response to transition from hyperoxia to hypoxia, and back again, as 
well as superimposed single action potentials, are shown below in Figure 2.  
 
 
 
 
 
 
Figure 2: A raw trace showing in vitro chemodischarge of the CSN. Discharge increased upon decreasing PO2 
from hyperoxic to hypoxic levels, which was reversed on return to hyperoxia. Pepper et al (1995).  
 
A gradually increasing discharge is seen between PaO2s of 400-140mmHg. At around 
100mmHg the slope of this response increases, reaching a maximum at ~30mmHg. The 
transmission of this discharge to the medulla results in a graded cardiorespiratory response 
including hyperventilation (an increased VE above metabolic demand, primarily via an 
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increased Rf), which decreases PACO2, increasing PAO2 and hence PaO2. Bradycardia, 
decreased cardiac output, peripheral vasoconstriction and an increased adrenomedullary output 
can also be triggered, although these can often be hidden by hyperventilation induced 
feedback responses e.g. by pulmonary stretch receptors (see review Marshall, 1999). In very 
severe hypoxia, discharge can decrease and the reflex response begins to fail (Kumar, 2007).  
Hypercapnia 
As previously mentioned, the CB can also respond to hypercapnia. The contribution of the CB 
to this response is generally thought to be small, with most of the response being mediated by 
central chemoreceptors. However it has been reported that the CBs may account for 30-50% 
of the hypercapnic ventilatory increase, even with a concurrent hyperoxia (Bruce and 
Cherniack, 1987, Heeringa et al, 1979, Nattie, 1999), although some of this response may be 
due to the CB reflex response leading to an increased central sensitivity (Blain et al, 2010). It 
has also been shown that dogs with isolated CBs perfused to maintain basal activity, show an 
increase in the time taken to respond to hypercapnia (Smith et al, 2006). Despite this 
significant contribution by the CB to the response to CO2, the majority of research has focused 
on the transduction of the O2 signal. In contrast to O2, where basal discharge persists even in 
hyperoxia, if PaCO2 falls below 18-25mmHg this basal discharge is stopped (Bartels et al, 
1956, Eyzaguirre and Lewin, 1961). Reduction in PaCO2 can also abolish discharge induced 
by hypoxia, although this may just be as a consequence of a non-physiological pH (Kumar and 
Prabhakar, 2012).  
CB chemoafferent discharge increases linearly up to around a PaCO2 of 65mmHg, after which 
it decreases and plateaus (Biscoe et al, 1970), however the amplitude of this discharge is 
smaller than that seen during hypoxia (Fitzgerald and Parks, 1971, Lahiri and Delaney, 1975, 
Pepper et al, 1995), which may again be due to an affect of the decreased pH on the type I cell 
secretory processes (Rocher et al, 2009).  
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The response to PaCO2 is faster than that to PaO2, which suggests that fluctuations in PaCO2 
may cause oscillating discharges in CB activity, presenting a candidate for the transmission of 
information to the brain during exercise (or situations of increased metabolism) (Band et al, 
1978, 1980, Kumar et al, 1988). This may be in association with some other blood-borne 
mediator such as a hormone (Bin Jaliah et al, 2005, Maskell et al, 2006), or via changes in 
[K+], as blood gas tension oscillations alone cannot fully explain VE changes in exercise and 
the reliability of signalling in this manner via the blood to the CB is questioned (Nye, 1994). 
As described, the three stimuli of the CB are responded to individually, potentially via a range 
of different sensors and transduction processes, but producing the same cardiorespiratory 
reflex response. The stimuli can also interact, potentiating this response beyond the simple 
sum of individual responses (Nielsen and Smith, 1952).  
As discussed, the VE response to a decrease in PaO2 is mediated solely by peripheral 
chemoreceptors, and is investigated by inhalation of hypoxic mixtures. Within this mixture 
PCO2 can be kept constant and under this condition PO2 has to fall to ~50mmHg before a 
ventilatory response is seen. However if PCO2 is increased in combination with hypoxia, VE 
will increase at a PO2 ~100mmHg. This is why CO2 is the major controller of VE, whilst PO2 
becomes more important in pathological conditions such as chronic lung disease where CO2 is 
chronically retained, or at altitude where decreased barometric pressure decreases the partial 
pressure of gases resulting in chronic hypoxia. PaCO2 is therefore held within a tight range. 
The ventilatory response to CO2 is usually investigated by inhalation of a gas mixture 
containing CO2 or a re-breathing technique, and in humans it has been shown that VE 
increases 2-3L.min-1 for each 1mmHg increase in PCO2. As mentioned, most of this response 
is mediated by the central chemoreceptors, but peripheral chemoreceptors respond more 
rapidly (West, 2012).  
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1.3  Glucoregulation  
Glucose is the main substrate utilised in metabolism to produce ATP and the only energy 
source utilised by the brain, and as such there is a requirement for a system by which plasma 
glucose levels are monitored and maintained within a set range (~4-7mmol/L). This is 
achieved by the existence of glucose sensitive sites, which are able to induce a neuroendocrine 
reflex response when stimulated by a change in plasma glucose levels.  The main glucose-
sensing sites that trigger this counter-regulatory response are peripheral; the pancreatic α and 
β-cells (Burcelin et al, 2008), the liver (Donovan et al, 1991), and the hepatic portal vein 
(Hevener et al, 1997), although some central centres are also sensitive to glucose (Burdakov et 
al, 2005). In response to hypoglycaemia, insulin secretion is halted to decrease uptake of 
glucose by e.g. skeletal muscle. Glycogenolysis (the breakdown of glycogen to glucose in the 
liver and skeletal muscle) and gluconeogenesis (production of glucose from the breakdown of 
glycerol and glutamine in adipose tissue (lipolysis) and the kidney respectively) can be 
stimulated to increase appearance of glucose in the blood. These pathways are regulated 
hormonally, for example catecholamines (adrenaline and noradrenaline) are released in 
response to low glucose. They can increase the rate of glycogenolysis by action at glucagon 
releasing α-pancreatic cells, and reduce insulin production and release by β-cells. Glucagon 
decreases the synthesis, and increases breakdown, of glycogen (the storage form of glucose). 
Both catecholamines and glucagon can also increase gluconeogenesis and glucose delivery to 
the blood in exercise or stress. Cortisol is also released in response to hypoglycaemia, and can 
potentiate the effects of glucagon, as well as increasing gluconeogenesis. Another of these 
counter-regulatory mediators is growth hormone, which acts to decrease tissue glucose uptake 
and increase both gluconeogenesis and lipolysis (Yeo and Sawdon, 2007). 
Insulin is the major hormone responding to increased blood glucose, and acts to increase 
expression of glucose transporters (e.g. GLUT-4), increase the synthesis of glycogen, with a 
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corresponding decrease in glucagon production, decrease in glucneogenesis and lipolysis and 
increase in triglyceride synthesis (another form of glucose storage) (Yeo and Sawdon, 2007). 
 
Figure 3 shows these major hormonal control pathways of plasma glucose: 
 
 
 
 
 
 
 
 
 
 
Figure 3: An overview of the hormonal control of plasma glucose levels. Image taken from Yeo and Sawden, 
(2007).  
 
1.4  Role for the CB in glucoregulation  
As well as the above established sites of glucose sensing, there is also a suggested role for the 
CB as a glucosensor. Due to the high blood flow and metabolic rate of the CB, it is well suited 
for a role in sensing a metabolic substrate such as glucose. However discrepancies in the data 
are present between species and preparation types and controversy exists over low glucose as a 
direct CB stimulus. 
For example, Almaraz et al (1984) showed no increase in neural discharge in response to low 
superfusate glucose concentration in an isolated cat CB preparation, or even a decrease in 
neurotransmitter release/discharge frequency in zero glucose for around 2 hours. After this 
time a small increase in activity has been seen, before tissue death (Conde et al, 2007). 
Another in vitro intact cat CB study showed that removal of glucose for 12 mins had no effect 
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on absolute release of neurotransmitters, also supporting no direct role for low glucose 
(Fitzgerald et al, 2009). 
 García-Fernández et al (2007) demonstrated the presence of GLUT-1, GLUT-3 and GLUT-4, 
but not the GLUT-2 glucose transporter in the rat CB, which has been shown to be essential 
for glucose sensitive cells via GLUT-2 -/- mice (Thorens, 2001).  CB cells have also been 
shown to express no glucokinase enzyme or specific KATP channel subunits that are expressed 
in liver, pancreatic cells and some central glucose sensitive neurons (Thorens, 2001). The fact 
that the CB does not possess these characteristics typical of other glucosensors, coupled with 
the discussed in vitro data, disagrees with any role for the CB in sensing low glucose directly. 
However there is also substantial evidence for a direct action of low glucose on the CB. In 
vitro studies have shown that low and zero glucose could elicit a dose-dependent increase in 
neurotransmitter secretion in rat and mouse thin CB slice preparations (Pardal & Lopez-
Barneo, 2002, Lopez-Barneo, 2003, Garcia-Fernadez, 2007), and co-cultures of rat CB type I 
cells (Zhang et al, 2007).  
An in vivo infusion of glucose into the vascularly isolated cat CB sinus reduced activity by 
20% and increased the threshold for the hypoxic response (Alvarez-Bullya, 1988). This group 
also showed that direct CB stimulation by sodium cyanide (a metabolic inhibitor) increased 
glucose output from the liver and increased brain retention of glucose, via an adrenal and sinus 
nerve mediated mechanism (Alvarez-Bullya, 1988, 1997). Intracarotid injections of glucose 
have also been shown to reduce the normal counter-regulatory response to hypoglycaemia in 
dogs (Frizzell, 1993).  
More recent in vivo studies have utilised the hyperinsulinaemic hypoglycaemic clamp protocol 
to investigate the role of the CB in glucoregulation. Koyama et al (2000) performed hypo- and 
euglycaemic clamps in conscious dogs. They showed that an increased glucose infusion was 
required to clamp plasma glucose after CBR (Figure 4) and that glucagon and cortisol counter-
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regulatory responses were significantly reduced. The adrenaline response was also reduced by 
50%, but not significantly.  
 
 
 
 
 
 
Figure 4: A graph showing the rate of glucose infusion required to maintain a hypoglycaemic plasma glucose 
clamp in conscious dogs. CBR (carotid body resected) animals required a higher infusion rate compared to 
shams, indicating a role for the CB in glucoregulation. Taken from Koyama et al (2000). 
  
They used the same methods to evaluate the role of the CB in maintaining plasma glucose 
during exercise (Koyama et al, 2001), and saw a mismatch between glucose production and 
disappearance at the onset of exercise, as well as blunted glucagon and noradrenaline counter-
regulatory responses in CBR animals. Although the authors suggested low glucose as the 
direct stimulus, the effect of the counter-regulatory hormones cannot be discounted.  
As hinted at previously, the CB possesses polymodality, whereby any of the stimuli to 
increase chemoafferent discharge results in the same set of cardiorespiratory reflexes. Based 
on this, hyperinsulinaemic hypoglycaemia, if acting at the CB, would be expected to induce a 
hyperventilation and associated hypocapnia. This was investigated by Bin Jaliah et al (2004) 
using eu- and hypoglycaemic clamp protocols in anaesthetised rats. An increased VE was seen 
in correlation with the decrease in plasma glucose levels in sham animals; whereas a reduced 
basal VE and no increased VE response to hypoglycaemia was seen in CSNX animals. 
However a corresponding in vitro preparation in the same lab showed no increase in single 
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fibre discharge in response to low or removed superfusate glucose, suggesting that low 
glucose was not the direct stimulus (Bin Jaliah, 2004, 2005). Moreover, in vivo, the 
hyperventilation seen in the sham animals was not accompanied by a hypocapnia, suggesting 
that the hyperinsulinaemic hypoglycaemia had increased metabolism, resulting in an isocapnic 
hyperpnoea. This was addressed by a consequent experiment (Bin Jaliah et al, 2005) using the 
same methods, which showed sham animals had an increased CO2 chemosensitivity in 
hypoglycaemia, not seen in the CSNX group. Again a corresponding in vitro preparation 
showed opposing results, with a low glucose superfusate blunting the response to increased 
CO2 (Bin Jaliah, 2005). These experiments suggest a potential role for the CB in matching VE 
to metabolism, posing a potential explanation for what is seen during exercise (as suggested 
by Band et al, 1978, 1980, Kumar et al, 1988). VE rises almost immediately, closely matching 
the increase in O2 consumption with increased CO2 excretion, maintaining arterial PCO2, O2 
and pH.  
As no response was seen in vitro, Bin Jaliah et al (2005) suggested that this increased 
peripheral CO2 sensitivity may be mediated hormonally, for example by adrenaline. This is 
not a new idea, as adrenaline has previously been suggested to play a role in exercise 
hyperpnoea (Linton et al, 1992), and increased levels of adrenaline are seen in both 
hypoglycaemia (Vollmer et al, 1997) and exercise (Christensen et al, 1983).              
Adrenaline, as well as other adrenoreceptor agonists, have previously been shown to increase 
ventilation in vivo (e.g. Whelan and Young, 1953, Young, 1957, Joels and White, 1968, 
Heistad et al, 1972, Maskell et al, 2006), an action which could be blocked by CSNX or 
application of hyperoxia (Joels and White, 1968, Heistad et al, 1972, Maskell et al, 2006) 
which is consistent with a direct action on the CB, rather than an action via the effect of 
adrenaline on blood flow. Joels and White (1968) showed that this increase in ventilation was 
accompanied by an increased chemoreceptor discharge. They also showed that a similar 
increase in ventilation and discharge could be achieved by infusion directly into the carotid 
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artery, and that this could be ablated by CSNX. Heistad et al (1972) and Maskell et al (2006) 
showed that the β-adrenoreceptor blocker propranolol was able to prevent the observed 
ventilatory responses, suggesting a potential mechanism.                                                  
However in vitro studies have revealed opposing results; adrenaline doses of 10-220µg, 
applied via the superfusate onto an isolated CB and sinus nerve, produced either no response 
or a decrease in chemodischarge (Eyzaguirre and Koyano, 1965). These findings have been 
replicated by co-workers, who saw a dose-dependent inhibition of afferent fibre discharge at 
doses of 1µM and above, and no effect at lower doses, in a similar CB preparation 
(unpublished data, Holmes and Kumar, 2011).  
Ward et al (2007) carried out hypo and hyperglycaemic clamp experiments in humans and 
showed that glucagon, cortisol, adrenaline and noradrenaline increased in response to 
hypoglycaemia (Figure 5), as did basal VE and the ventilatory response to hypoxia.  
 
 
 
 
 
 
 
 
 
Figure 5:  A series of graphs showing that levels of glucagon, adrenaline, noradrenaline and cortisol were all 
increased in response to hypoglycaemia. Taken from Ward et al (2007). 
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This is consistent with an effect of hypoglycaemia on the CB, but again cannot rule out the 
possibility of mediation via the release of the counter-regulatory hormones rather than low 
glucose directly. Wehrwein et al (2010) also carried out hypoglycaemic clamps in humans, but 
under normoxia or hyperoxia to isolate CB involvement. The glucose infusion required to 
maintain the clamp was 45% higher and the normal counter-regulatory hormonal response was 
significantly blunted under hyperoxia i.e. without CB input (Figure 6).  
 
 
 
 
 
Figure 6:  A shows the glucose infusion rate required to maintain a plasma glucose clamp was increased in the 
presence of hyperoxia i.e. when CB function was ablated. G shows that the amount of counter-regulatory 
hormone release under hyperoxia was reduced compared to normoxic conditions. Taken from Wehrwein et al, 
(2010). 
 
This supports the hypothesis originally proposed by Koyama et al (2000) that intact CB’s are 
required for a normal response to hypoglycaemia, but still does not clarify whether low 
glucose is the stimulus, or whether it could be adrenaline. 
 
 
 
 
 
 
16 
 
2.  Aims and Hypotheses 
The CB is a peripheral chemoreceptor responding to changes in arterial gas tensions and pH. It 
has also been proposed to have a role in glucoregulation, although it is unknown whether the 
direct stimulus is low glucose or some other blood-borne mediator such as a counter-
regulatory hormone. 
Based on the current evidence, this project aimed to further investigate the role of the CB in 
glucoregulation, specifically with respect to how the CB is stimulated in hypoglycaemia e.g. 
directly by low glucose or by the associated counter-regulatory hormone adrenaline. The 
interaction between hypoglycaemia/adrenaline and the hypercapnic ventilatory response was 
also investigated.  
The hypotheses were as follows: 
• Administration of the hypoglycaemic counter-regulatory hormone adrenaline would activate 
the CB via β-adrenoreceptors, increasing basal VE. Hyperoxia and propranolol would ablate 
CB-mediated increases in VE.  
• Administration of the counter-regulatory hormone adrenaline would increase hypercapnic 
sensitivity. 
• Basal VE would increase during an insulin-induced hypoglycaemic ramp. Hyperoxia and 
propranolol would ablate this CB–mediated increase in VE. 
• Hypercapnic sensitivity would be increased during hypoglycaemia.  
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3.  Methods 
3.1   Animals 
Male Wistar rats were sourced from Charles River Laboratories, with body weights of 260-
415g on the day of experimentation. The animals were housed in single sex groups, at a 
temperature of 21±1°C and humidity of 40-45%, under a 12-hour light/dark cycle (lights on at 
7:00am). Food and water was available ad libitum, until food was withdrawn from midnight 
before experimentation to ensure stable and consistent basal blood glucose levels. 
The care of the animals and all procedures performed were carried out by Home Office 
licensees in line with the Home Office (UK) guidelines, University of Birmingham guidelines 
on ethical use of animals and the Animals (Scientific Procedures) Act (UK) 1986.  
 
3.2   Anaesthesia and surgery 
Anaesthesia was induced with 4% isoflurane in O2 at 4 L min-1 (Merial Animal Health Ltd.). 
Surgery was then carried out as follows (see Figure 7): the right jugular vein was isolated and 
cannulated (ID 0.5mm, OD 1.5mm), allowing maintenance of anaesthesia with a 17-20 mg.kg-
1.hour-1 infusion of Alfaxan® (Vétoquinol UK Ltd.) using a syringe driver (Perfusor® 
securaFT, B. Braun.), and 0.1ml boluses as necessary. The trachea was isolated and 
cannulated with a stainless steel T-piece cannula. The right brachial artery was isolated from 
the brachial plexus and cannulated (ID 0.4mm, OD 0.8mm). The right femoral artery and vein 
were isolated from the femoral sheath and cannulated (ID 0.58mm, OD 0.96mm, and 3 x ID 
0.28mm, OD 0.61mm, each soldered to an ID 0.58mm, OD 0.96mm, respectively). The left 
femoral artery was isolated.   
Plane of anaesthesia was monitored throughout by assessing response to a strong paw pinch. 
Core body temperature was also monitored and maintained at 37°C throughout, via a rectal 
temperature probe linked to a homeothermic heat pad system (Harvard Apparatus) the animal 
was positioned upon. All cannulae were filled with heparinised saline (20 Units/ml Heparin, 
18 
 
LEO® Pharma) and sourced from Portex™, Smiths Medical. Suture was from Look®, 
Surgical Specialities Corporation and needles (0.5x25, 0.6x30mm and 0.8x40mm, 
Microlance™) and syringes (1, 2, 5 and 10ml, Plastipak™) were from BD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: A diagram showing the surgical set-up used. The jugular vein was cannulated to allow infusion of 
anaesthetic (Alfaxan, 17-20mg.kg-1hr-1). The trachea was cannulated to allow airflow to be monitored via a 
spirometer, allowing respiratory frequency (Rf) and tidal volume (Vt) to be derived. The brachial artery was 
cannulated to record mean arterial blood pressure (MABP), from which heart rate (HR) was derived. The right 
femoral artery was cannulated with a specialised line for taking blood samples. The femoral vein was cannulated 
with 3 cannulae soldered to larger cannulae, to allow multiple drug infusions. The left femoral artery was isolated 
to allow measurement of femoral blood flow (FBF) using a flow probe. Femoral vascular conductance (FVC = 
FBF/MABP) and ventilation (VE = Rf x Vt) were also calculated. 
 
3.3  Equipment and data 
A spirometer (MacLab, ADInstruments) was attached to the tracheal T-piece to measure 
airflux, allowing calculation of respiratory frequency (Rf), tidal volume (Vt) and minute 
ventilation (VE = Rf  x Vt). Animals breathed room air, but a plastic tube running from 
cylinders of N2, O2 (Boc) and CO2 (Murex) could be attached to the spirometer via a t-piece, 
allowing control of inspired gases by a rotameter (Cole Parmer).  
A pressure transducer (Capto) was attached to the brachial cannula to monitor arterial blood 
pressure (ABP) (via a MacLab Bridge Amp, ADInstruments), from which mean ABP and HR 
were derived. Blood samples were taken via a specialised femoral artery cannula, which 
minimised blood loss and ensured a pure sample. The samples were used to monitor blood 
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glucose (Accu-Chek®, Aviva), blood gases and haematocrit (150µl capillary tubes and Gem® 
4000 premier analyser, Instrumentation Laboratory Ltd.). The isolated femoral artery had a 
flow probe (Transonic Systems Inc.) attached to monitor femoral blood flow (FBF), an index 
of hindlimb skeletal muscle blood flow, and also allowing calculation of femoral vascular 
conductance (FVC = MFBF/MABP). The cannulae in the femoral vein were used to give drug 
infusions (see section 3.4) using syringe drivers (kd Scientific). Data was recorded at sampling 
frequencies of 100-1000 samples/second, using PowerLab and Labchart software 
(ADInstruments) on a Mac OS X computer. The experimental set-up is shown in Figure 8 
below. 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: A photograph showing the experimental set-up used. A spirometer was attached to the tracheal T-piece 
to measure airflux, allowing calculation of respiratory frequency (Rf), tidal volume (Vt) and minute ventilation          
(VE = Rf  x Vt). A plastic tube provided a gas supply from cylinders of N2, O2 and CO2, which could be attached to 
the spirometer via a t-piece. A pressure transducer was attached to the brachial cannula to monitor arterial blood 
pressure (ABP), from which MABP and HR were derived. Blood samples were taken via a specialised cannula in 
the right femoral artery. The cannulae in the right femoral vein were used to give drug infusions. The isolated left 
femoral artery had a flow probe attached to monitor femoral blood flow (FBF), also allowing calculation of 
femoral vascular conductance (FVC = MFBF/MABP). Core body temperature was monitored and maintained at 
37°C via a rectal temperature probe linked to a homeothermic heat pad system. 
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3.4  Drugs 
Adrenaline (E4250 - Sigma®) and propranolol (P0884 - Sigma®) were dissolved in saline. 
Insulin (Hypurin® Bovine Neutral, CP Pharmaceuticals Ltd.) was made up in Gelofusine® 
plasma expander (4% w/v, Dechra Veterinary Products) and infused using a 10ml glass 
syringe (81601, Hamilton) to minimise adherence to the equipment.  
 
3.5  Experimental protocols 
Before any experiment, 40 minutes post-surgery stabilisation was allowed. A 20-minute 
baseline was then recorded, during which blood glucose was sampled at 0, 10 and 20 minutes, 
and a blood gas was taken at 20 minutes. Blood glucose and gas samples were then taken 
periodically throughout each experiment. 
 
3.5.1 - Group 1: The effect of adrenaline on ventilation 
The effect of adrenaline on ventilation was investigated (n=6) using infusions at 
concentrations between 0.1ng–1µg.kg-1.min-1. 5 minutes was allowed for each dose to reach a 
steady state, before CB-mediated effects were determined with 30 seconds exposure to 100% 
O2 (hyperoxia) which resulted in PaO2s  > 300 mmHg, and was also carried out at baseline. 
After recovery from adrenaline, a 0.3mg.kg-1min-1 propranolol infusion was given (n=5) for 10 
minutes to reach a steady baseline, before a control hyperoxia was carried out. The adrenaline 
dose-response was then repeated in the presence of propranolol. 
 
Group 2: Hypercapnic ventilatory sensitivity 
The effect of adrenaline on the hypercapnic ventilatory response (CO2 sensitivity = Δ VE / 
mmHg  PaCO2) was determined (n=5) using a constant infusion of 1µg.kg-1min-1. The dose 
was allowed 5 minutes to reach a steady state, before the animal was exposed to graded levels 
of hypercapnia: 4 and 8% inspired CO2 for 5 minutes. Adequate time was allowed between 
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each hypercapnia for recovery to baseline values. Subsequent blood gas analysis revealed that 
the presumed 4% level of hypercapnia did not significantly alter PaCO2 from basal values, 
whereas the 8% level gave PaCO2 levels of 57 ± 1.3 mmHg, therefore this level was used 
subsequently. This level of hypercapnia was also carried out at baseline, prior to 
administration of adrenaline, to obtain a control response. After recovery from adrenaline, 
propranolol was given as described above (n=2) and the hypercapnic response assessed. The 
adrenaline infusion was then repeated in the presence of propranolol, and the hypercapnia (61 
± 4.5 mmHg) repeated.     
 
3.5.2  Group 3: Hyperinsulinaemic hypoglycaemic ramp 
Insulin was infused at different rates between 2 - 12 mU.kg-1min-1 in order to achieve 3 – 4 
target levels of hypoglycaemia (blood glucose of 5.7 (basal) to 2.9 mmol/L) (n=6)). Each level 
was maintained for around 10 minutes, allowing the effect on basal ventilation to be recorded, 
before 30 seconds exposure to hyperoxia was used to determine CB-mediated input. At the 
most severe level of hypoglycaemia, the hypercapnic ventilatory response (CO2 sensitivity) 
was assessed by exposure to a PaCO2 of 58 ± 0.9 mmHg for 5 minutes. Basal ventilation and 
control responses to hyperoxia and hypercapnia were also recorded at euglycaemia. The 
protocol was then repeated in the presence of a 0.3mg.kg-1min-1 propranolol infusion (n=6). 
Control responses were carried out after 10 minutes propranolol infusion, before the insulin 
infusion was restarted (hypercapnia causing PaCO2 levels of 56 ± 1 mmHg). Blood samples 
were taken throughout the ramp protocols with a view to measuring the levels of the counter-
regulatory hormone adrenaline (see section 6 - future work).  
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3.6  Data analysis 
All data is presented as the mean ± SEM of the absolute data or as the difference from baseline 
or corresponding control response. Graphs were plotted in DeltaGraph 5.7.5, and statistics 
carried out using GraphPad Prism.  
The effect of adrenaline on VE, with hyperoxia and/or propranolol, was plotted as a scatter 
graph and analysed using repeated measures or one-way ANOVAs as appropriate, with post-
hoc Bonferroni tests. Paired or unpaired t-tests were used to compare specific pairs of VE 
responses and to analyse the cardiovascular and blood glucose data.   
The effect of hypoglycaemia on VE, with hyperoxia and/or propranolol, was plotted as a 
scatter graph and had linear regression lines fitted. The slope of each data set was analysed 
statistically using one sample t-tests (to compare each line to zero) and one-way ANOVA with 
post-hoc Bonferroni was used to compare appropriate pairs of slopes. Paired t-tests were used 
to analyse the cardiovascular data.  
The hypercapnic ventilatory responses under control conditions, in the presence of 
adrenaline/hypoglycaemia and with or without propranolol, were also plotted as scatter 
graphs. The slopes of these lines were plotted as bar charts representing CO2 sensitivity (Δ VE/ 
mmHg PaCO2). One-way ANOVAs, with post-hoc Bonferroni tests were carried out to 
compare the CO2 sensitivities within each experimental group. Paired and unpaired t-tests 
were also used to compare specific pairs of data.    
The relationship between PaCO2 and VE during adrenaline infusion/hypoglycaemia, and the 
effect of propranolol on this relationship was plotted as a scatter graph. Linear regression lines 
were fitted to each. The slopes were compared to zero using one-sample t-tests and to each 
other using unpaired t-tests. All data was analysed to the 95% significance level i.e. P <0.05 
taken as significant.    
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4.  Results 
4.1  Group 1 
The effect of adrenaline on ventilation 
Figure 9 A shows raw traces of ABP, HR, airflux, Rf, Vt and FBF at baseline and during 
infusion of 1µg.kg-1min-1 adrenaline. The main effects seen were increased Rf and Vt, as well 
as increased FBF, MABP and decreased HR. The cardiovascular effects of adrenaline are 
summarised in Table 1, reflecting the changes shown in the traces, although none reached 
significance. Adrenaline also caused a significant increase in [blood glucose] from a basal 
value of 6.6 ± 0.5 to 7.3 ± 0.5mmol.L-1 at 1µg.kg-1min-1 (paired t-test, P < 0.05). 
Figure 9 B shows an adrenaline dose-response curve; adrenaline caused a significant increase 
in VE from a basal value of 133.5 ± 4.1 to 151.9 ± 6.8 ml.min-1 at the highest dose. However 
VE did not increase progressively with each dose tested, only becoming significant at 0.1 and 
1µg.kg-1min-1. It was therefore inappropriate to fit a dose-response curve or linear regression 
line, or to continue repeating the full range of doses, therefore 0, 0.1 and 1µg.kg-1min-1 were 
used from this point. 
The effect of hyperoxia and propranolol 
Figure 10 shows raw traces showing the effects of hyperoxia and propranolol, compared to 
control. Hyperoxia decreased Rf, reflected in the Vt trace. Hyperoxia also significantly 
decreased HR and FBF. Whilst this trace shows no significant effect on ABP, overall MABP 
significantly increased, as shown by group mean data in Table 2 (paired t-tests vs control, P < 
0.05). The major effect of propranolol alone was to cause a significant decrease in HR 
(cardiovascular data shown in Table 1), as well as a significantly decreased ABP and a slight 
but non-significant decrease in FVC (as seen in the FBF trace). Rf slightly decreased 
compared to control, but not by as much as in hyperoxia. There was no significant difference 
between the HR and MABP with propranolol alone and propranolol with adrenaline infusion. 
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There was a significant difference in FVC, however the value recorded with propranolol and 
adrenaline together was not significantly different from the control value (Table 1). 
Figure 11 A shows the selected adrenaline doses increasing VE (i.e. normoxia). Hyperoxia 
significantly shifted the response down, but VE still increased with adrenaline. Propranolol 
also shifted the response down (not as far as hyperoxia), but VE still increased with adrenaline. 
However at the top dose, propranolol appears to partly reduce the response, although this did 
not quite reach significance (unpaired t-test, P = 0.0519). Propranolol did not alter the effect of 
adrenaline on blood glucose as levels still rose, from 6.9 ± 0.5 basally, to 7.3 ± 0.4 at 1µg.kg-1 
min-1 adrenaline, but not significantly. The combination of hyperoxia and propranolol was 
additive (significances shown on graph from repeated measures ANOVA & post hoc 
Bonferroni, comparing means of each line).                                                                                                                          
Figure 11 B shows the effect of hyperoxia, propranolol and the combination, as the difference 
from the response at each corresponding adrenaline dose. The hyperoxia and combination 
differences remained fairly stable at each dose, whereas the propranolol difference slightly, 
but not significantly, increased at the top dose (one-way ANOVAs & post-hoc Bonferroni, P > 
0.05) reflecting the reduced response in A. 
The effect of adrenaline on PaCO2  
Figure 12 shows the association between the increased VE caused by adrenaline (from baseline 
to1µg.kg-1min-1), and the PaCO2 levels sampled at the corresponding doses. In normoxia i.e. 
the control response to adrenaline, VE increased and PaCO2 remained constant, showing just a 
slight decrease. In the presence of propranolol, adrenaline still increased VE, but not by as 
much as in control, as seen in Figure 11 A. However PaCO2 increased. Statistics could not be 
carried out on this data as not every animal the ventilation data was drawn from had a 
corresponding blood gas taken, and vice versa, and so this plot can only suggest a trend from 
the data available.  
25 
 
4.2  Group 2 
The effect of adrenaline on hypercapnic ventilatory sensitivity 
Figure 13 shows raw traces demonstrating the response to hypercapnia, the main effect of 
which was an increased Vt, and slightly increased Rf. HR and FVC decreased and BP slightly 
increased in this hypercapnic trace compared to control, but mean group data showed no 
significant cardiovascular effects of hypercapnia (paired t-tests vs control, P > 0.05, shown in 
Table 3). The 3rd trace shows hypercapnia in the presence of adrenaline; Vt is increased as in 
the 1st hypercapnic response, but Rf increased further. HR and ABP appear increased 
compared to the 1st response, which may be accounted for by an effect of the adrenaline. 
Figure 14 A shows the hypercapnic ventilatory response at control, and with adrenaline and 
propranolol. Adrenaline increased basal ventilation and also increased the response to CO2. 
Propranolol alone and with adrenaline reduced this response to below the control. Figure 14 B 
shows the slopes of the hypercapnic responses i.e. CO2 sensitivity, demonstrating that there 
was no significant difference between any of the slopes. 
 
4.3  Group 3 
The effect of hypoglycaemia, hyperoxia and propranolol, on ventilation 
Figure 15 shows raw traces demonstrating the effect of hypoglycaemia; Rf increased, reflected 
in the Vt trace. ABP stayed constant, but HR and FBF showed an increase (the 3rd trace shows 
a hypercapnic response during hypoglycaemia – see Figure 18). However, Table 4 shows that 
hypoglycaemia had no significant effect on the cardiovascular parameters (paired t-tests vs 
control, P > 0.05). Figure 16 A shows basal ventilation and three levels of insulin-induced 
hypoglycaemia causing an increased VE. A one-way ANOVA with post-hoc Bonferroni 
showed no significant increase in VE overall or between each pair of blood glucose levels. 
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Hyperoxia shifted the response down, but VE still increased at each blood glucose level. 
Propranolol appeared to prevent the increase, with VE actually decreasing. Hyperoxia and 
propranolol in combination showed an additive effect, shifting VE down and preventing the 
increase. However, as this data was not paired and each animal had slightly different blood 
glucose values, linear regression fits were deemed more useful in assessing the relationship 
between hypoglycaemia and VE. Slopes for each response were determined and plotted as a 
bar chart in Figure 16 B. Normoxia (the control response to hypoglycaemia) vs. hyperoxia, 
and propranolol vs. hyperoxia with propranolol were not significantly different, but all other 
slopes were significantly different from each other (one-way ANOVA and post-hoc 
Bonferroni, P < 0.05) and all slopes were significantly different from 0 (one-sample t tests, P < 
0.05).  
The effect of hypoglycaemia on PaCO2 
Figure 17 is a scatter graph showing the association between the increased VE caused by 
hyperinsulinaemic hypoglycaemia, and PaCO2. Under the normoxic conditions i.e. the control 
response to hypoglycaemia, VE increased and PaCO2 remained constant. In the presence of 
propranolol, VE decreased in spite of the hypoglycaemia (as seen in Figure 16 A), and PaCO2 
increased. However comparison of the slopes of the fitted linear regression lines showed no 
significant difference between the two conditions (unpaired t-test, P > 0.05), and that neither 
was significantly different from 0 (one-sample t-tests, P > 0.05), potentially due to the large 
error bars.  
The effect of hypoglycaemia on hypercapnic ventilatory sensitivity 
The 3rd raw trace of Figure 15 shows an example hypercapnic response in hypoglycaemia, 
which resembles the trace seen in hypoglycaemia alone, except Vt also increased.  Figure 18 A 
shows the control hypercapnic ventilatory response, and the corresponding responses in 
hypoglycaemia, with propranolol alone and in combination with hypoglycaemia.  
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Hypoglycaemia increased VE basally, and caused an increased response to CO2. The response 
with propranolol was not different from control, but the response during hypoglycaemia and 
propranolol infusion was blunted to below control levels. The slopes of these response lines 
provided a measure of CO2 sensitivity, represented by the bar chart in Figure 18 B. The 
significances shown on the slopes are two-fold: one-way ANOVA with post-hoc Bonferroni 
showed no significant difference between the control vs hypoglycaemic, control vs 
propranolol and propranolol vs hypoglycaemia & propranolol CO2 sensitivities, and 
significant differences between hypoglycaemic/control vs hypoglycaemic & propranolol 
sensitivities. The animals were not paired between all groups, however a paired t-test could be 
carried out between control and hypoglycaemia, revealing a significant difference (P < 0.05), 
and an unpaired t-test between hypoglycaemia and hypoglycaemia with propranolol confirmed 
significance (P < 0.05).        
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Table 1: Cardiovascular effects of adrenaline and propranolol 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Mean group cardiovascular data ± SEM. Adrenaline had no significant effect on any of the mean 
cardiovascular parameters, although MABP and FVC both increased (paired t-tests vs control, P > 0.05). 
Propranolol alone significantly decreased HR and MABP (P < 0.05) but had no significant effect on FVC (paired 
t-tests vs. control, P > 0.05). Adrenaline had no significant effect on HR or MABP during propranolol infusion, 
but FVC did significantly increase (paired t-tests propranolol vs adrenaline and propranolol, P < 0.05). However 
the FVC seen with adrenaline and propranolol was not significantly different to control (paired t-test adrenaline 
and propranolol vs control, P > 0.05). 
 
Table 2: Cardiovascular effects of hyperoxia 
 
 
 
 
 
Table 2: Mean group cardiovascular data ± SEM. Hyperoxia significantly increased MABP, and decreased HR 
and FVC (paired t-tests vs control, P < 0.05). 
 
Mean ± SEM Control 
 
Adrenaline 
1µg.kg-1min-1 
Propranolol 
 
Adrenaline & 
propranolol 
HR (bpm) 449 ± 7.7 448 ± 11.9 (ns) 369 ± 5.4 (*) 374 ± 13.9 (ns) 
MABP 
(mmHg) 
123 ± 2.2 132 ± 4.7 (ns) 109 ± 3.8 (*) 
 
120 ± 7.9 (ns) 
FVC (U) 0.023 ± 0.003 0.026 ± 0.005 (ns) 0.021 ± 0.002 (ns) 
 
0.026 ± 0.002 (*/ns) 
Mean ± SEM Control Hyperoxia 
HR (bpm) 449 ± 8.7 438 ± 7.2 (*) 
MABP (mmHg) 123 ± 2.6 129 ± 2.6 (*) 
FVC (U) 0.023 ± 0.003 0.019 ± 0.002 (*) 
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Table 3: Cardiovascular effects of hypercapnia 
 
 
 
 
 
Table 3: Mean group cardiovascular data ± SEM. Hypercapnia had no significant effect on HR, MABP or FVC 
(paired t-tests vs control, P > 0.05). 
 
 
Table 4: Cardiovascular effects of hypoglycaemia 
 
 
 
 
 
Table 4: Mean group cardiovascular data ± SEM. Hypoglycaemia had no significant effect on HR, MABP or 
FVC (paired t-test vs control, P > 0.05). 
 
 
 
 
Mean ± SEM Control Hypercapnia 
HR (bpm) 449 ± 8.7 425 ± 9.0 (ns) 
MABP (mmHg) 123 ± 2.6 120 ± 3.7 (ns) 
FVC (U) 0.023 ± 0.003 0.025 ± 0.003 (ns) 
Mean ± SEM Control Hypoglycaemia 
HR (bpm) 449 ± 8.7 453 ± 10.5 (ns) 
MABP (mmHg) 123 ± 2.6 123 ± 4.5 (ns) 
FVC (U) 0.023 ± 0.003 0.024 ± 0.003 (ns) 
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Figure 9: The effect of adrenaline on ventilation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 A: Raw traces showing baseline recordings of ABP, HR, airflux, Rf, Vt and FBF, and the effect of 
1µg.kg-1min-1 adrenaline upon them. The main effects of this adrenaline dose were increased Rf, Vt, ABP and 
FBF, and a decreased HR. Mean cardiovascular data is shown in Table 1. B: An adrenaline dose-response curve; 
adrenaline significantly increased VE (repeated measures ANOVA, P < 0.05) but not between every dose tested, 
reaching significance at 0.1 and 1µg.kg-1min-1 (post-hoc Bonferroni).   
 
1 sec 
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Figure 10: The effect of hyperoxia and propranolol (raw traces) 
 
 
 
 
 
 
 
Figure 10: Raw traces showing the effects of hyperoxia and propranolol, compared to control. The main effect of 
hyperoxia was a decreased Rf. Hyperoxia also significantly decreased HR and FBF. Whilst this trace shows no 
significant effect on ABP, overall MABP significantly increased, as shown by group mean data in Table 1 (paired 
t-tests vs control, P < 0.05). The major effect of propranolol was to cause a significant decrease in HR 
(cardiovascular data shown in Table 1), as well as a significantly decreased ABP and a slight but non-significant 
decrease in FVC (as seen in the FBF trace). Rf slightly decreased compared to control, but not as much as with 
hyperoxia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 sec 
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Figure 11: The effect of hyperoxia and propranolol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: A - The selected adrenaline doses increased VE (= normoxia). Hyperoxia significantly shifted the 
response down, but VE still increased with adrenaline. Propranolol also shifted the response down, but not as far 
as hyperoxia.  VE still increased with adrenaline at the first dose, however at the top dose, propranolol appears to 
partly reduce the response, although this didn’t reach significance (unpaired t-test, P = 0.0519). The combination 
of hyperoxia and propranolol was additive (signifcances shown on graph from repeated measures ANOVA & 
post hoc Bonferroni, comparing means of each line). B: The effect of hyperoxia, propranolol and the 
combination, shown as the difference from the response at each corresponding adrenaline dose. The hyperoxia 
and combination differences remained fairly stable at each dose, whereas the propranolol difference slightly, but 
not significantly, increased at the top dose (one-way ANOVAs & post-hoc Bonferroni, P > 0.05). 
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Figure 12: The effect of adrenaline on PaCO2 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: A scatter graph showing the association between the increased VE caused by adrenaline (only baseline 
and top dose shown), and the PaCO2 levels sampled at the corresponding doses. Under normoxia i.e. the control 
response to adrenaline, VE increased and PaCO2 remained almost constant, showing just a slight decrease. In the 
presence of propranolol, adrenaline still increased VE, but not by as much as in control, as seen in Figure 11 A. 
However PaCO2 increased.  
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Figure 13: The effect of adrenaline on hypercapnic ventilatory sensitivity (raw traces) 
 
 
 
 
 
 
 
 
Figure 13: Raw traces showing the response to hypercapnia, the main effect of which was an increased Vt, and 
slightly increased Rf. HR and FBF also appear slightly decreased in this example, however none of the mean 
cardiovascular changes in response to hypercapnia were significant (data shown in Table 3, paired t-tests vs 
control, P > 0.05). The 3rd trace shows hypercapnia in the presence of adrenaline; Vt is increased as in the 1st 
hypercapnic response, but Rf increased further. HR and ABP appear increased compared to the 1st response, 
which may be accounted for by an effect of the adrenaline. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 sec 
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Figure 14: The effect of adrenaline on hypercapnic ventilatory sensitivity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: A- The effect of hypercapnia on ventilation under different conditions. Adrenaline increased basal 
ventilation and also increased the response to CO2. Propranolol alone and with adrenaline reduced this response 
to below the control. B: The slopes of the hypercapnic responses (CO2 sensitivity) shown as a bar chart, 
demonstrating that the increased response with adrenaline and decreased responses with propranolol (with and 
without adrenaline) were not significant (one-way ANOVA with post-hoc Bonferroni comparing each group, P > 
0.05). Propranolol experiments were only carried out in n = 2, and so paired and unpaired t-tests were also carried 
out, also revealing no significance (P > 0.05). 
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Figure 15: The effect of hypoglycaemia, hyperoxia and propranolol, on ventilation (raw 
traces) 
 
 
 
 
 
 
 
 
Figure 15: Raw traces showing the effect of hypoglycaemia; Rf increased, reflected in the Vt trace. ABP stayed 
constant, but HR and FBF showed an increase (3rd raw trace shows a hypercapnic response in hypoglycaemia – 
see Figure 18). However, as shown in Table 4, hypoglycaemia had no significant effect on the cardiovascular 
parameters (paired t-tests vs control, P > 0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 sec 
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Figure 16: The effect of hypoglycaemia, hyperoxia and propranolol, on ventilation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: A - Linear regression lines showing basal ventilation and three levels of insulin-induced 
hypoglycaemia causing an increased VE. Hyperoxia shifted the response down, but VE still increased at each 
blood glucose level. Propranolol appeared to prevent the increase, with VE actually decreasing. Hyperoxia and 
propranolol together showed an additive effect, shifting VE down and preventing the increase. B: Slopes for each 
linear regression in A plotted as a bar chart. Normoxia (the control response to hypoglycaemia) vs hyperoxia, and 
propranolol vs hyperoxia with propranolol were not significantly different, but all other slopes were significantly 
different from one another (one-way ANOVA and post-hoc Bonferroni, P < 0.05) and from 0 (one-sample t-tests, 
P < 0.05).  
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Figure 17: The effect of hypoglycaemia on PaCO2 
 
 
 
 
 
 
 
Figure 17: A scatter graph showing the association between the increased VE caused by hyperinsulinaemic 
hypoglycaemia, and PaCO2. Under the normoxic conditions i.e. the control response to hypoglycaemia, VE 
increased and PaCO2 remained constant. In the presence of propranolol, VE decreased in spite of the 
hypoglycaemia, and PaCO2 increased. However, comparison of the slopes of the fitted linear regression lines 
showed no significant difference between the two conditions (unpaired t-test, P > 0.05), and that neither was 
significantly different from 0 (one-sample t-tests, P > 0.05).  
 
 
 
 
 
 
 
 
 
 
39 
 
Figure 18: The effect of hypoglycaemia on hypercapnic ventilatory sensitivity 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
Figure 18: A - The control hypercapnic ventilatory response, and the corresponding responses in hypoglycaemia, 
with propranolol alone and in combination with hypoglycaemia. Hypoglycaemia increased VE basally, and also 
showed an increased response to CO2. The response with propranolol was not different from control, but the 
response during hypoglycaemia and propranolol infusion was blunted to below control levels. B: Slopes of each 
response line in A (CO2 sensitivity), represented as a bar chart. The significances shown on the slopes are two-
fold: one-way ANOVA with post-hoc Bonferroni showed no significant difference between the control vs 
hypoglycaemic, control vs propranolol and propranolol vs hypoglycaemia with propranolol CO2 sensitivities, and 
significant differences between hypoglycaemic/control vs hypoglycaemic with propranolol sensitivities. A paired 
t-test between control and hypoglycaemia revealed a significant difference (P < 0.05), and an unpaired t-test 
between hypoglycaemia and hypoglycaemia with propranolol confirmed significance (P < 0.05).      
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5.  Discussion 
5.1  The effect of adrenaline on ventilation and the hypercapnic ventilatory response 
Adrenaline caused a significant increase in VE when administered as an intravenous infusion 
at 0.1 and 1µg.kg-1min-1, supporting a wealth of data regarding the action of adrenaline to 
increase respiration (e.g. Whelan and Young, 1953, Young, 1957, Joels and White, 1968, 
Heistad et al, 1972, Maskell et al, 2006). For example, Whelan and Young (1953) showed an 
increased Rf and Vt after intravenous administration of adrenaline at 10-20µg.min-1, which was 
at its largest during the initial 5 minutes, in line with the infusion length allowed here before 
respiratory measurements were made. The choice of dose in the present study is justified by 
the performance of a dose-response curve to observe the effect of a range of doses upon 
ventilation. The literature reports use of a wide range of doses, although it has been reported 
that the respiratory response is more readily seen at smaller (µg) doses (Young, 1957), as 
demonstrated by Linton et al (1992), who showed an increased VE at 1µg.kg-1min-1, but no 
effect at 0.1 µg.kg-1min-1. No significant effect of adrenaline at the doses used in the present 
study was seen upon cardiovascular parameters. A slight increase in FVC was seen, which 
coupled with the lack of effect on blood pressure suggests that the VE response seen to 
adrenaline is a direct action on the CB cells rather than an indirect effect via reducing CB 
blood flow. 
 
Hyperoxia was used to isolate any CB-mediated input to the response to adrenaline, and was 
seen to reduce the offset in the ventilatory response to adrenaline. However hyperoxia did not 
block the action of adrenaline (as observed by Joels and White, 1968, and Heistad et al, 1972), 
as VE still increased during adrenaline infusion. Propranolol significantly decreased HR, as 
well as MABP, demonstrating its widely reported role as a β-adrenoreceptor antagonist. The 
dose used was the same as that used by Maskell et al (2006). The cardiovascular data recorded 
during concurrent adrenaline and propranolol infusion was inconclusive. HR was still reduced 
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compared to control and not significantly different to propranolol alone, however MABP 
increased and FVC increased significantly. This either suggests that the β block was 
incomplete and so the β action of adrenaline to cause vasodilatation was still able to occur, or 
that an α action of adrenaline was responsible. For example adrenaline could have acted via α 
receptors to increase MABP (by vasoconstriction), activating a baroreceptor reflex resulting in 
decreased sympathetic output to muscle. This would cause vasodilatation and therefore an 
increased FVC. Another possibility is that an α-mediated metabolic action of adrenaline 
resulted in release of some by-product which was responsible for the cardiovascular changes. 
Propranolol showed a similar effect to hyperoxia on VE, except at 1 µg.kg-1min-1 adrenaline 
where the VE response appeared slightly (but not significantly) reduced.  
 
Taken together, these data suggest that the action of adrenaline on VE is CB independent, or 
that O2 and adrenaline act via independent pathways within CB. This latter possibility is 
supported by the fact that the response with hyperoxia and propranolol in combination was 
additive rather than multiplicative, suggesting no interaction between pathways. Previous 
studies have supported this idea of independent transduction pathways within the CB, for 
example Zhang et al (2007) showed that the in vitro response to hypoglycaemia and 
hypoxia/hypercapnia were additive, and Garcia-Fernandez et al (2007) showed that a 
metabolic inhibitor blocked the response to hypoxia but not to low glucose.  
 
It must also be considered whether the hyperoxia applied here was sufficient to ablate CB 
function, as Kumar et al (2007) reported that a tonic in vivo firing could still be seen at PO2s 
in excess of 400mmHg, whilst Biscoe et al (1970) reported in vivo single afferent fibre firing 
up to 600mmHg. Therefore it is likely that the > 300 mmHg PaO2 utilised here did not fully 
ablate CB function, explaining why hyperoxia did not completely prevent the response to 
adrenaline. This is supported by Heistad et al (1972) who described, in man, that 100% O2 
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could block the increased ventilation seen in response to an i.v. infusion of a β-agonist. 
Additionally they showed that propranolol could also block this ventilatory response, thus 
further supporting a β- and CB-mediated increase in VE.  
 
Although we were unable to measure metabolic rate in our study, we found that the increased 
ventilation in response to adrenaline was independent of PaCO2 thus suggesting that the 
increased VE seen was an appropriate hyperpnoea in response to increased metabolic rate, 
rather than a hyperventilation, as observed by Bin Jaliah et al (2004) and Maskell et al (2006). 
Whelan and Young (1953) reported a fall in alveolar CO2 and increased O2 consumption 
during adrenaline infusion, which they described as calorigenic i.e. metabolic, although they 
also suggested the increased respiration may have been independent of the increased metabolic 
rate.  
It is known that increased metabolism can be induced by adrenaline via both adrenoreceptor 
groups. α receptors activate downstream pathways inducing liver and adipose tissue 
glycogenolysis and gluconeogenesis, inhibition of insulin release and stimulation of glucagon 
release from the pancreas. Stimulation of β receptors (via increased cAMP levels) can also 
lead to increased glucagon release and lipolysis (Rang and Dale, 2006). Hence metabolic 
effects of adrenaline can be primarily attributed to α-action, whilst the respiratory actions are 
suggested to be via β receptors, as demonstrated by Heistad et al (1972) and Maskell et al 
(2006). Therefore, in the current study, adrenaline should have increased both VE and 
metabolism, but the primary effect of propranolol would have been upon VE. However the α-
actions of adrenaline to increase metabolism would have been unaffected (Rang and Dale, 
2006, Yeo and Sawdon, 2007), as supported by the fact that blood glucose still increased in 
the presence of propranolol (although this was not significant, potentially due to the higher 
baseline levels seen with propranolol alone). This would explain the increased PaCO2 seen 
during β-block. This rise in PaCO2 would be expected to stimulate central chemoreceptors, and 
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this increased central chemoreceptor drive is the most likely explanation for the increased VE 
which was still seen during adrenaline infusion despite the presence of propranolol. These 
data, coupled with the lack of cardiovascular effects of adrenaline i.e. no α-mediated increase 
in ABP and no β-mediated increase in HR, but just a slight increase in FVC, suggests that 
different tissues can have different sensitivities to adrenaline, possibly via different 
adrenoreceptor subtypes. 
 
Adrenaline showed a trend to increase CO2 sensitivity in the present experiment, increasing 
the hypercapnic ventilatory response, which could subsequently be reduced by propranolol. 
Maskell et al (2006) have also shown that adrenaline (at a higher dose of 10µg.kg-1min-1) 
increases CO2 sensitivity, and that this was abolished by CSNX, hence it was CB-mediated. 
They also showed the increased chemosensitivity was blocked by infusion of propranolol 
(0.3mg.kg-1min-1, as used here), supporting the present data, and showing that the effect was 
β-mediated. Along with the present data showing no change in PaCO2 with the increased VE 
associated with adrenaline infusion, and that this hyperpnoea could be prevented by 
propranolol, the trend for an increased CO2 sensitivity supports the hypothesis by Maskell et 
al (2006); that adrenaline may be one of the blood-borne factors that mediate hyperpnoea by 
an action on CO2 chemosensitivity. 
 
5.2  The effect of hyperinsulinaemic hypoglycaemia on ventilation 
A decreased blood glucose caused an increased VE, with a linear regression slope significantly 
different to zero. This has been shown previously by Bin Jaliah et al (2004, 2005) and Ward et 
al (2007). Bin Jaliah et al (2004) isolated the role of the CB, showing reduced basal VE and no 
increased VE in response to hypoglycaemia in CSNX animals, supporting a role for the CB in 
mediating the increased VE seen.  
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It has previously been shown that hypoglycaemia is associated with an increased release of 
counter-regulatory hormones including adrenaline (Vollmer et al, 1997, Koyama et al, 2000, 
2001, Ward et al, 2007, Yeo and Sawdon, 2007, Wehrwein et al, 2010). Both the increased VE 
and counter-regulatory hormone release has been shown to be reduced by CBR (Koyama et al, 
2000, 2001) or application of hyperoxia (Wehrwein et al, 2010), suggesting a CB-dependency 
of the effect. This mechanism explains the need for an increased glucose infusion to clamp 
plasma glucose during hyperinsulinaemia, in absence of CB input (Koyama et al, 2000, 2001, 
Wehrwein et al, 2010). These findings are consistent with the results of the present study, 
where hyperoxia reduced the ventilatory response to hypoglycaemia. However, hyperoxia did 
not block the response, with a constant difference between normoxic and hyperoxic VE at each 
blood glucose resulting in a slope that was offset, but not different from control (normoxia).  
However propranolol was able to abolish the increase in VE that was seen in hypoglycaemia.  
This suggests that the rise in VE associated with hypoglycaemia is β-dependent. Taken in 
combination with the hyperoxia data, this suggests that the increased VE in hypoglycaemia is 
either a CB independent mechanism, or that an O2-independent pathway exists within the CB 
for sensing hypoglycaemia (supported by Garcia-Fernandez et al, 2007 and Zhang et al, 2007, 
as discussed above). The fact that the effect of hyperoxia and propranolol together appeared 
additive (slope not significantly different from propranolol alone), supports this idea of 
independent pathways within the CB.  
 
As mentioned above, given the reports that in vivo CB afferent firing can still be seen at PaO2s 
of up to 400-600mmHg (Kumar, 2007, Biscoe et al 1970), it is likely that the level of 
hyperoxia used here did not fully ablate CB function, offering further explanation as to why a 
VE response to hypoglycaemia was still seen and supporting a CB-dependent mechanism.  
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This is further supported by the evidence for a CB role in glucosensing (see section 1.4), and it 
therefore seems unlikely that these data represent a CB-independent ventilatory response to 
hypoglycaemia.  
 
The data therefore disagrees with the results of in vitro studies that suggest the CB responds to 
low glucose directly (Pardal and Lopez-Barneo, 2002, Lopez-Barneo, 2003, Garcia-Fernandez 
et al, 2007, Zhang et al, 2007). In addition the present data contradicts the speculations from 
in vivo studies such as Koyama et al (2000, 2001) and Wehrwein et al (2010), which suggest, 
but provide no direct evidence for, low glucose acting directly on the CB. It also offers in vivo 
support for those in vitro studies that showed no effect of low glucose on chemoafferent 
discharge; despite showing an in vivo increase in VE during hypoglycaemia, which was 
ablated by CSNX (Bin Jaliah et al, 2004, 2005). Based on this data, Bin Jaliah et al (2004, 
2005) suggested a potential role for one of the associated counter-regulatory hormones as a 
blood-borne mediator sensed by the CB, a possibility that was also recognised by Ward et al 
(2007). Given the present data showing that propranolol was able to block the VE response to 
hypoglycaemia, this blood-borne mediator may be adrenaline. 
 
The relationship seen between hypoglycaemia and PaCO2 suggests that the increased VE seen 
was a hyperpnoea rather than a hyperventilation, as PaCO2 remained constant. This suggests 
that the hyperinsulinaemic hypoglycaemia caused an increased metabolism, which is 
consistent with previous findings by Bin Jaliah et al (2004, 2005). In the present study, PaCO2 
fell slightly, as was also seen in response to adrenaline. However, this fall does not appear 
large enough to be explained by a hyperventilation. For example, a fall in PaCO2 of around 
5mmHg was observed in response to a 20% increase in VE generated in response to graded 
hypoxia (i.e. a hyperventilation) (Marshall and Metcalfe, 1988), whereas we only observed a 
fall of around 1mmHg in response to a hypoglycaemia- (and presumably adrenaline-) 
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mediated 15% increase in ventilation. This is in line with data reported by Forster and Pan 
(1994), where PaCO2 only changes by 1-2mmHg in human exercise (a situation of increased 
metabolism).   
In the presence of propranolol, both hypoglycaemia and adrenaline did not induce as much of 
an increased VE, and PaCO2 increased. This suggests that propranolol prevented the increase in 
VE that is usually matched to the increased metabolism i.e. it occurs via a β-mediated 
mechanism, whilst metabolism was still able to increase via the action of adrenaline at α 
receptors, as well as via the other associated counter-regulatory hormones in hypoglycaemia. 
However, the data presented did not show statistically significant results, possibly due to the 
high variability associated with the VE data.   
 
The effect of hyperinsulinaemic hypoglycaemia on hypercapnic ventilatory sensitivity 
 Bin Jaliah et al (2005) showed an increased CO2 chemosensitivity during hypoglycaemia 
which was reduced by ~75% after CSNX, presenting a possible CB-mediated mechanism by 
which PaCO2 could remain constant during increased metabolism. Increasing the sensitivity of 
the chemoreceptors for CO2 would lead to an increased VE, facilitating matching to the 
increased CO2 production associated with increased metabolism. This was demonstrated in the 
present study, where the ventilatory response to hypercapnia was increased during 
hypoglycaemia, showing a significantly increased CO2 sensitivity. Bin Jaliah et al (2005) also 
showed that a fall in glucose concentration decreased CO2 sensitivity in an in vitro CB 
preparation, suggesting that the in vivo increase in CO2 sensitivity and hyperpnoea was not via 
a direct action of low glucose. This was supported by the present finding that propranolol was 
able to block, and even significantly reduce, the increased CO2 sensitivity associated with 
hypoglycaemia, suggesting a β-mediated mechanism i.e. adrenaline.  
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5.3  Comparison of the responses to adrenaline and hypoglycaemia 
The response to application of exogenous adrenaline and hyperinsulinaemic hypoglycaemia 
are similar; both causing an increase in VE of similar magnitude (~20ml.min-1). Both responses 
were affected similarly by application of hyperoxia, i.e. VE was reduced, but still showed an 
increase with increasing stimulus intensity. This may be explained by the fact that the CB was 
not completely switched off by the hyperoxia, or, based on the assumption that CB activity 
was reduced, suggests that the responses were either independent of the CB or sensed via O2 
independent pathways within the CB. Propranolol had differing effects, causing a small but 
non-significant decrease in the VE response to 1µg.kg-1min-1 adrenaline, but causing a 
complete attenuation of the increased VE caused by hypoglycaemia, with VE even decreasing. 
The application of hyperoxia and propranolol in combination had an additive effect in both 
experiments, supporting the idea of independent pathways within the CB for different stimuli 
i.e. O2 and adrenaline/low glucose. 
 
The maintenance of PaCO2 during the increased VE caused by both adrenaline and 
hypoglycaemia, suggested that metabolic rate had increased and the observed increase in VE 
was a hyperpnoea as opposed to a hyperventilation. In the presence of propranolol in both 
experimental groups, PaCO2 showed a tendency to rise, although this did not reach statistical 
significance in either group. These data suggest that metabolism rises via an α-receptor 
mechanism, whilst matching VE to this metabolism is β-dependent. 
 
Finally, CO2 sensitivity was increased during infusion of adrenaline and significantly during 
insulin-induced hypoglycaemia, which would provide a mechanism for the ability to maintain 
isocapnia in the face of increased metabolism.  
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Based on these findings and the knowledge that adrenaline is a major counter-regulatory 
hormone released in response to hypoglycaemia (Vollmer et al, 1997, Koyama et al, 2000, 
2001, Yeo and Sawdon, 2007, Ward et al, 2007, Wehrwein et al, 2010), it would not be 
unreasonable to conclude that the hyperinsulinaemic hypoglycaemia had caused endogenous 
release of adrenaline, and that this adrenaline caused the respiratory responses observed via β-
receptors, as the response was reduced by propranolol. When taken alongside previous studies 
already discussed, which have suggested the CB does not respond to low glucose directly (e.g. 
Almaraz et al, 1984, Conde et al, 2007, Fitzgerald et al, 2009) but to some other blood borne 
mediator (Bin Jaliah et al, 2004, 2005) and that adrenaline can increase VE and CO2 sensitivity 
via CB-dependent mechanisms (Heistad et al, 1972, Maskell et al, 2006), it may be suggested 
that this data demonstrates a β-receptor and CB-dependent role for adrenaline in situations of 
increased metabolism.  
 
A physiological example of such a situation is exercise. The CBs have been shown to play a 
neuroendocrine role during exercise, as demonstrated by Koyama et al (2001). They showed 
that CBR dogs had reduced levels of glucagon and noradrenaline released during exercise 
compared to sham animals, and a mismatch between glucose use and production, thus also 
linking back to the proposed role in glucoregulation. 
An immediate matching of VE to metabolism is seen in exercise, maintaining isocapnia or 
slight hypocapnia, as well as normoxia and normal arterial pH. Although peripheral 
chemoreceptors are not thought to be the major mediators of the hypercapnic response, they 
do give a rapid response to increased PCO2, increasing VE. The timing of this response 
therefore fits with the almost immediate increase in VE seen during exercise. Based on the 
present experiment and literature, this fast response to increased CO2 from increased 
metabolism may be mediated by an increased CB CO2 chemosensitivity, which is potentially 
mediated by adrenaline, either directly or indirectly via increased sympathetic activity.  
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Further implicating the CB in exercise hyperpnoea is the evidence that the response is 
depressed in CBR subjects compared those with intact carotid bodies (Honda, 1985, 
Wasserman et al, 1975).  
The ventilatory response to exercise is in three phases: phase I shows the rapid increase in VE 
that occurs at the start of the exercise, or even in anticipation before exercise begins, phase II; 
an exponential increase in VE during dynamic exercise, and phase III; a steady-state of VE.     
It is recognised that the major cardiovascular and respiratory controller in exercise is a central 
feed-forward mechanism. Afferent reflexes then provide additional input e.g. respiratory 
muscle metaboreceptors, locomotor muscle afferents and the CBs (for review see Dempsey, 
2012). It has been proposed that the CBs are involved in phases II and III, maintaining PaCO2 
and preventing hypoxia, providing around a 20% proportion of the ventilatory drive in phase 
III (Ward, 1994, Whipp, 1994). However, Dempsey and Smith (1994) have shown in various 
animal models that the CB inhibits respiratory motor output during heavy exercise, and 
Forster and Pan (1994) ascribed the CB a role in ‘fine tuning’ ventilation during submaximal 
exercise, but no major role in exercise hyperpnoea.  
 
5.4  A possible role for potassium 
It has long been shown that adrenaline can cause a decrease in plasma K+ levels (D’Silva, 
1934), although some have reported an increase in K+ associated with adrenaline infusion 
(Linton et al, 1992). It has been observed that this plasma K+ lowering action of adrenaline is 
via a β2-receptor dependent action on the Na+/K+ ATPase pump, moving K+ into cells 
(Clausen, 1983). This is particularly important in exercise, when K+ leaks from cells and the 
adrenaline released in association with exercise acts to counter this hyperkalaemia (Lancet 
editorial, 1983, Clausen, 1983). Insulin can have the same effect as adrenaline on K+, as 
observed by Bin Jaliah et al (2004), who reported a decrease in arterial K+ levels during a 
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hyperinsulinaemic clamp protocol.  However this is via a non-β dependent mechanism 
(Minaker and Rowe, 1982).   
 
In relation to the current experiment, adrenaline infusion would have driven K+ into cells, 
causing hyperpolarisation of all cells, including CB type I cells. This would increase the 
threshold for excitation of the CB and may explain why the dose-response of adrenaline 
against VE was complex.  In the presence of propranolol, any direct β effect of adrenaline on 
the CB to increase VE would be lost. Additionally, the action of adrenaline on the Na+/K+ 
ATPase acting via β2 receptors would also be blocked, thus unmasking any effect of K+. This 
is supported by the observation that β-blockers can cause hyperkalaemia, especially during 
exercise when adrenaline levels are increased (Clausen, 1983). Band and Linton (1986) 
showed that an infusion of KCl produced hyperkalaemia in cats similar to that seen during 
exercise, resulting in a significantly increased carotid body chemoafferent firing. The K+ levels 
increased the level and amplitude of oscillations in CB afferent firing which aligned with 
respiration and have previously been suggested to play a role in the control of breathing during 
exercise (Band et al, 1978, 1980, Kumar et al, 1988). It was therefore suggested that K+ may 
underlie this role (Band and Linton, 1986, Nye, 1994). This may explain why adrenaline still 
caused an increase in VE during propranolol infusion.  
 
Insulin also drives K+ plasma levels down in a dose-dependent manner, via the Na+/K+ 
ATPase, but via a non-β mediated mechanism (Minaker and Rowe, 1982). This means that the 
hyperinsulinamic hypoglycaemia would have also been accompanied by a hypokalaemia, 
which would then be further accentuated by the release of counter-regulatory adrenaline. 
Hence the increased VE seen was a balance between the effect of increased adrenaline and low 
K+.  When propranolol was given in hypoglycaemia, the effect of adrenaline on K+ would be 
removed; however the β-independent effect of insulin would still be present, meaning that 
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plasma K+ levels would continue to decrease. In this situation, propranolol is presumably 
blocking the adrenaline drive to VE, and insulin is reducing the K+ drive (unlike the situation 
with adrenaline and propranolol). This may therefore offer an explanation as to why VE was 
seen to decrease with propranolol during hypoglycaemia.   
 
5.5  Methodological limitations 
Limitations are recognised within the experiments carried out. For instance a control 
hyperinsulinaemic euglycaemic clamp was not carried out to control for effect of the high 
insulin infusion itself. However this has been carried out previously by co-workers (Bin Jaliah 
et al, 2004, 2005) who showed no direct effect of insulin on the CB.  
 
A steady PaCO2 during an increased VE was taken to indicate a hyperpnoea in the presence of 
increased metabolism. However, use of plethysmography or a spirometer attached to a sealed 
system would have allowed for evaluation of O2 consumption or CO2 production, which are 
indicators of metabolic activity.  
 
Total VE was used to here to represent the respiratory response to adrenaline, hypoglycaemia 
and hypercapnia; however there was no determination of physiological dead space. The 
amount of gas that was available for gas exchange, the alveolar VE (VA) would have been 
smaller than the data reported. We did not record this and therefore have had to assume VA to 
be a constant fraction of total VE. 
 
Hyperoxia was used in this investigation to ‘chemically denervate’ the CB. However it has 
been shown that even at a PaO2 of 400-600mmHg, some in vivo basal firing remains (Kumar, 
2007, Biscoe et al, 1970) and if CO2 is not controlled for, there will still be CB activity (see 
section 1.2 - hypercapnia). Therefore it must be accepted that the hyperoxia used here 
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probably reduced but did not ablate CB activity. This may explain why hyperoxia did not 
prevent the VE increases seen in response to adrenaline and hypoglycaemia, supporting a role 
for the CB in mediating the observed responses.  
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6.  Future work 
Based on the findings of the current study, several pieces of future work could be carried out 
to help consolidate the conclusions and address the ideas raised by the data:  
Measurement of plasma adrenaline from the blood samples taken during the 
hyperinsulinaemic hypoglycaemic ramp should be carried out in order to confirm the release 
of adrenaline and compare the concentration seen to the dose given exogenously in the first set 
of experiments. Koyama et al (2000) reported adrenaline concentrations of around 300pg.ml-1 
in response to hypoglycaemia, much lower than the exogenous dose of 1µg.kg-1min-1 
administered here.  It may also be prudent to repeat the adrenaline dose-response protocol, 
taking blood samples at each dose to measure the concentration of adrenaline in the blood, e.g. 
using HPLC as performed by Maskell et al (2006). The exogenous dose given would have 
been subject to possible uptake mechanisms and metabolism, and so does not represent the 
circulating levels.   
The experiments which used hyperoxia to isolate the role of the CB could be repeated using 
CSNX or CBR, surgically removing CB input and allowing comparison with the current 
results. This would determine whether the level of hyperoxia used was ablating all of the CB 
input and therefore if the increased VE and CO2 sensitivity seen during exogenous adrenaline 
infusion and hyperinsulinaemic hypoglycaemia are CB-dependent mechanisms.   
The experiments could also be repeated using a β-agonist such as isoprenaline, in order to 
reconcile the inconclusive cardiovascular data seen here with adrenaline and propranolol.  
Considering the potential role of K+ in the increased VE seen with adrenaline and hypercapnia, 
an improvement for future experiments would be to have the ability to measure K+ levels. This 
can often be determined from the sample taken for blood gas analysis, and so would not 
require further blood sampling or an increased protocol time.  
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As it is known that the CB possesses functional plasticity, changes in chemoreceptor 
sensitivity may occur in response to conditions with exposure to chronic/intermittent hypoxia 
such as obstructive sleep apnoea. These diseases may be associated with the co-morbidity of 
diabetes, presenting an opportunity for the possible alteration of the glucoregulatory response. 
Investigation of such conditions in terms of CB function may offer new therapeutic targets.   
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7.  Conclusion 
This study provides evidence for a role of adrenaline, a counter-regulatory hormone released 
in response to hypoglycaemia, in the hyperpnoea of hypermetabolism. The data generated thus 
supports a body of literature that suggests that the ventilatory response to hypoglycaemia is 
not mediated by a direct action of low glucose on the CB, but the action of an associated 
blood-borne mediator.  
The observation that CO2 sensitivity was augmented during adrenaline infusion and 
hypoglycaemia, offers a mechanism by which VE could be matched to metabolism in the 
absence of a change in PaCO2. Reduction of the increased VE, CO2 sensitivity and hyperpnoea 
by the β-antagonist propranolol confirms the β-dependence of the mechanism.  Further 
experiments are required to confirm whether adrenaline acts via the CB, in an O2 independent 
manner or whether the level of hyperoxia used was able to fully isolate the role of the CB.  
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